FDA approves first factor XIa inhibitor after stroke; MRI brain-age model predicts decline; review finds bypass triage evidence insufficient

A tuning fork with clamp-on weights on its tines standing upright beside a reflex hammer.

The Food and Drug Administration (FDA) approved Bayer's asundexian (Sunharbo), the first factor XIa inhibitor, with antiplatelet therapy to reduce stroke risk after recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack. A deep learning brain-age model built on T1-weighted MRI predicted clinical worsening, and a meta-analysis found evidence insufficient for routine prehospital bypass to comprehensive stroke centers.

  • FDA Nov 9, 2026
    The Food and Drug Administration (FDA) approved Bayer's Sunharbo (asundexian) 50 mg tablets on Nov. 9 for use with antiplatelet therapy after a recent mild-to-moderate non-cardioembolic ischemic stroke or high-risk transient ischemic attack. In the phase 3 OCEANIC-STROKE trial, 12,327 adults randomized within 72 hours of symptom onset had a 26% lower risk of ischemic stroke than with placebo over a median treatment of 14.2 months, according to the FDA. Major bleeding was similar overall but rose in patients older than 75 years and in the first 90 days. The drug is not approved for stroke prevention in atrial fibrillation.
    Sources: FDA, NeurologyLive
  • AI Nov 11, 2026
    A brain-age estimation framework built with freely available Python tools was trained on T1-weighted MRI from 4,346 cognitively normal adults, according to a retrospective Radiology: Artificial Intelligence study published online Nov. 11. Mean absolute error for chronological age was 3.76 years internally and 4.82 to 5.15 years in two external test sets of 315 and 209. In a clinical cohort of 954 people, the brain-age gap was associated with white matter hyperintensity severity (odds ratio 1.64) and stroke history (odds ratio 1.46), not with amyloid positivity after full adjustment (P = .17), and predicted clinical worsening (hazard ratio 1.92).
  • Research Nov 10, 2026
    A systematic review and meta-analysis published online in Neurology on Nov. 10 pooled 18 studies, including two randomized trials, of severity-based triage for direct transport to the nearest comprehensive stroke center. Bypass was associated with earlier groin puncture (median 63.9 minutes earlier) and more functional independence at 90 days (odds ratio 1.23, 95% CI 1.04 to 1.45), but in randomized trials time to needle was 34 minutes longer, and in intracerebral hemorrhage bypass was associated with higher mortality (risk ratio 1.30, 95% CI 1.02 to 1.64). The authors said evidence is insufficient to recommend routine bypass protocols.
    Sources: Neurology, PubMed

The weekly innovation roundup for neurology, published every Sunday for the week before; every item links to its sources. Latest neurology news · All specialties

Latest news

Tagged neurology, from the daily briefing

  1. DEA places the narcolepsy drug oveporexton in Schedule IV, effective immediately
  2. Synchron pauses trials of its wireless brain implant and cuts jobs, saying the pause is not safety related
  3. Brain implants let people with ALS speak and sing, The New York Times reports

See all the latest news